CRMD - CorMedix Inc

CRMD - CorMedix Inc

https://www.cormedix.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

Zacks Commentary • 1 hour, 19 minutes ago • score: 0.37

CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.

Strategic Sale: Elizabeth Hurlburt Decides To Exercise Options Worth $635K At Cormedix - Cormedix ( NASDAQ:CRMD )

Benzinga • 3 days ago • score: 0.44

In a new SEC filing on September 12, it was revealed that Hurlburt, Chief Operating Officer at Cormedix CRMD, executed a significant exercise of company stock options. What Happened: Disclosed in a Form 4 filing on Friday with the U.S.

Major Exercise Alert: Beth Zelnick Kaufman Exercises Options Worth $495K At Cormedix - Cormedix ( NASDAQ:CRMD )

Benzinga • 3 days ago • score: 0.45

In a new SEC filing on September 12, it was revealed that Kaufman, Chief Legal Officer at Cormedix CRMD, executed a significant exercise of company stock options. What Happened: Disclosed in a Form 4 filing on Friday with the U.S.

CorMedix ( CRMD ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Commentary • 6 days, 1 hour ago • score: 0.46

After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.

52W High

$17.43

52W Low

$5.37

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.77

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

15.90

Forward P/E (<15 better)

5.99

EV/EBITDA (<8 favorable)

14.07

EV/Revenue (<3 favorable)

6.05

P/S (TTM) (<3 favorable)

7.62

P/B (<3 favorable)

4.20

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

7.49%

Institutions (25–75% balanced)

46.79%

Shares Outstanding

74,649,000

Float

69,269,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

121,484,000

Gross Profit (TTM)

116,163,000

EPS (TTM)

0.78

Profit Margin (>10% good)

0.42%

Operating Margin (TTM) (higher better)

0.49%

ROE (TTM) (>15% strong)

0.38%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

48.29

Momentum

Bearish momentum

Value

0.6229

Previous

0.7999

Trend

Falling

Signal Cross

No cross

As of

Sep. 04, 2025